Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

被引：3

作者：

Liebers, Nora ^{[1
,2
,3
,4
,5
]}

Boumendil, Ariane ^{[6
]}

Finel, Herve ^{[6
]}

Edelmann, Dominic ^{[7
]}

Kobbe, Guido ^{[1
,4
]}

Baermann, Ben-Niklas ^{[1
,4
]}

Serroukh, Yasmina ^{[8
]}

Blaise, Didier ^{[9
]}

Beelen, Dietrich Wilhelm ^{[10
]}

Solano, Carlos ^{[11
]}

Itaelae-Remes, Maija ^{[12
]}

van Meerten, Tom ^{[13
]}

Choi, Goda ^{[13
]}

Schmidt, Susanne Anna Christine ^{[1
,4
]}

Kroeger, Nicolaus ^{[14
]}

Byrne, Jenny ^{[15
]}

Tudesq, Jean-Jacques ^{[16
]}

Ossami Saidy, Anna ^{[17
]}

Nunes, Ana ^{[18
]}

Siddiqi, Rubina ^{[18
]}

Baro, Elande ^{[18
]}

Zheng, Dan ^{[18
]}

Kloos, Ioana ^{[18
]}

Dreger, Peter ^{[5
,6
]}

Sureda, Anna ^{[6
,19
]}

Glass, Bertram ^{[6
,17
]}

Dietrich, Sascha ^{[1
,4
,5
,6
]}

机构：

[1] Univ Hosp Duesseldorf, Dept Hematol Oncol & Clin Immunol, Moorenstr 5, D-40225 Dusseldorf, Germany

[2] Natl Ctr Tumor Dis NCT Heidelberg, Dept Translat Med Oncol, Heidelberg, Germany

[3] German Canc Res Ctr, Heidelberg, Germany

[4] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldor, Cologne, Germany

[5] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany

[6] European Soc Blood & Marrow Transplantat, Lymphoma Working Party, Paris, France

[7] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[8] Erasmus MC, Univ Med Ctr Rotterdam, Dept Hematol, Canc Inst, Rotterdam, Netherlands

[9] Inst Paoli Calmettes, Marseille, France

[10] Univ Hosp Essen, Essen, Germany

[11] Univ Valencia, Hosp Clin Univ INCLIVA, Valencia, Spain

[12] Univ Hosp Turku, Turku, Finland

[13] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands

[14] Univ Med Ctr Hamburg, Hamburg, Germany

[15] Univ Nottingham, Nottingham, England

[16] CHU Lapeyronie, Montpellier, France

[17] HELIOS Klinikum Berlin Buch, Dept Hematol, Berlin, Germany

[18] Kite, Gilead Co, Santa Monica, CA USA

[19] Univ Barcelona, Inst Catala Oncol LHospitalet, Clin Hematol Dept, IDIBELL, Barcelona, Spain

来源：

BLOOD CANCER DISCOVERY | 2025年 / 6卷 / 03期

关键词：

INTERNATIONAL BLOOD; THERAPY; DISEASE; TUMORS;

D O I：

10.1158/2643-3230.BCD-24-0178

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed and refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 patients aged >= 50 years with r/r MCL treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (of 272) patients with r/r MCL who underwent alloHCT using data from the European Society for Blood and Marrow Transplantation registry. The median follow-up time was 36.5 months for the brexu-cel cohort and 34.1 months for the matched alloHCT cohort. Patients who received brexu-cel had a significantly higher overall survival [(OS) 81.3% vs. 59.2%; HR, 0.39; P = 0.004] and lower nonrelapse mortality (3.6% vs. 21.2%; P = 0.015) 1 year after treatment. Chronic GVHD occurred within the first year in 26.9% of patients who underwent alloHCT. However, long-term progression-free survival (PFS) and OS remain comparable. Despite the limitations of this nonrandomized study, the findings indicate a superior safety profile for brexu-cel in r/r MCL.Significance: Patients aged >= 50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk-benefit evaluation is essential to guide optimal treatment decisions.

引用

页码：182 / 190

页数：9

共 21 条

[11] The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL [J].

Rejeski, Kai ;

Wang, Yucai ;

Albanyan, Omar ;

Munoz, Javier ;

Sesques, Pierre ;

Iacoboni, Gloria ;

Lopez-Corral, Lucia ;

Ries, Isabelle ;

Buecklein, Veit L. L. ;

Mohty, Razan ;

Dreyling, Martin ;

Baluch, Aliyah ;

Shah, Bijal ;

Locke, Frederick L. L. ;

Hess, Georg ;

Barba, Pere ;

Bachy, Emmanuel ;

Lin, Yi ;

Subklewe, Marion ;

Jain, Michael D. D. .

AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) :1699-1710

[12] Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party [J].

Robinson, Stephen P. ;

Boumendil, Ariane ;

Finel, Herve ;

Peggs, Karl S. ;

Chevallier, Patrice ;

Sierra, Jorge ;

Finke, Juergen ;

Poire, Xavier ;

Maillard, Natacha ;

Milpied, Noel ;

Yakoub-Agha, Ibrahim ;

Koh, Mickey ;

Kroeger, Nicolaus ;

Nagler, Arnon ;

Koc, Yener ;

Dietrich, Sascha ;

Montoto, Silvia ;

Dreger, Peter .

BONE MARROW TRANSPLANTATION, 2018, 53 (05) :617-624

[13] Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study [J].

Sandoval-Sus, Jose D. ;

Faramand, Rawan ;

Chavez, Julio ;

Puri, Sonam ;

Parra, Paola ;

Sokol, Lubomir ;

Kharfan-Dabaja, Mohamed A. ;

Shah, Bijal ;

Ayala, Ernesto .

LEUKEMIA & LYMPHOMA, 2019, 60 (02) :309-316

[14] A note on quantifying follow-up in studies of failure time [J].

Schemper, M ;

Smith, TL .

CONTROLLED CLINICAL TRIALS, 1996, 17 (04) :343-346

[15] The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis [J].

Selberg, Lorenz ;

Stadtherr, Peter ;

Dietrich, Sascha ;

Tran, T. Hien ;

Luft, Thomas ;

Hegenbart, Ute ;

Bondong, Andrea ;

Meissner, Julia ;

Liebers, Nora ;

Schmitt, Michael ;

Ho, Anthony Dick ;

Mueller-Tidow, Carsten ;

Dreger, Peter .

BONE MARROW TRANSPLANTATION, 2021, 56 (01) :30-37

[16] Long-Term Sustained Disease Control in Patients With Mantle Cell Lymphoma With or Without Active Disease After Treatment With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning [J].

Vaughn, Jennifer E. ;

Sorror, Mohamed L. ;

Storer, Barry E. ;

Chauncey, Thomas R. ;

Pulsipher, Michael A. ;

Maziarz, Richard T. ;

Maris, Michael B. ;

Hari, Parameswaran ;

Laport, Ginna G. ;

Franke, Georg N. ;

Agura, Edward D. ;

Langston, Amelia A. ;

Rezvani, Andrew R. ;

Storb, Rainer ;

Sandmaier, Brenda M. ;

Maloney, David G. .

CANCER, 2015, 121 (20) :3709-3716

[17] Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study [J].

Wang, Michael ;

Munoz, Javier ;

Goy, Andre ;

Locke, Frederick L. ;

Jacobson, Caron A. ;

Hill, Brian T. ;

Timmerman, John M. ;

Holmes, Houston ;

Jaglowski, Samantha ;

Flinn, Ian W. ;

McSweeney, Peter A. ;

Miklos, David B. ;

Pagel, John M. ;

Kersten, Marie Jose ;

Bouabdallah, Krimo ;

Khanal, Rashmi ;

Topp, Max S. ;

Houot, Roch ;

Beitinjaneh, Amer ;

Peng, Weimin ;

Fang, Xiang ;

Shen, Rhine R. ;

Siddiqi, Rubina ;

Kloos, Ioana ;

Reagan, Patrick M. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) :555-+

[18] KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma [J].

Wang, Michael ;

Munoz, Javier ;

Goy, Andre ;

Locke, Frederick L. ;

Jacobson, Caron A. ;

Hill, Brian T. ;

Timmerman, John M. ;

Holmes, Houston ;

Jaglowski, Samantha ;

Flinn, Ian W. ;

McSweeney, Peter A. ;

Miklos, David B. ;

Pagel, John M. ;

Kersten, Marie-Jose ;

Milpied, Noel ;

Fung, Henry ;

Topp, Max S. ;

Houot, Roch ;

Beitinjaneh, Amer ;

Peng, Weimin ;

Zheng, Lianqing ;

Rossi, John M. ;

Jain, Rajul K. ;

Rao, Arati V. ;

Reagan, Patrick M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (14) :1331-1342

[19] Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial [J].

Wang, Michael ;

Rule, Simon ;

Zinzani, Pier Luigi ;

Goy, Andre ;

Casasnovas, Olivier ;

Smith, Stephen D. ;

Damaj, Gandhi ;

Doorduijn, Jeanette ;

Lamy, Thierry ;

Morschhauser, Franck ;

Panizo, Carlos ;

Shah, Bijal ;

Davies, Andrew ;

Eek, Richard ;

Dupuis, Jehan ;

Jacobsen, Eric ;

Kater, Arnon P. ;

Le Gouill, Steven ;

Oberic, Lucie ;

Robak, Taduesz ;

Covey, Todd ;

Dua, Richa ;

Hamdy, Ahmed ;

Huang, Xin ;

Izumi, Raquel ;

Patel, Priti ;

Rothbaum, Wayne ;

Slatter, J. Greg ;

Jurczak, Wojciech .

LANCET, 2018, 391 (10121) :659-667

[20] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma [J].

Wang, Michael L. ;

Rule, Simon ;

Martin, Peter ;

Goy, Andre ;

Auer, Rebecca ;

Kahl, Brad S. ;

Jurczak, Wojciech ;

Advani, Ranjana H. ;

Romaguera, Jorge E. ;

Williams, Michael E. ;

Barrientos, Jacqueline C. ;

Chmielowska, Ewa ;

Radford, John ;

Stilgenbauer, Stephan ;

Dreyling, Martin ;

Jedrzejczak, Wieslaw Wiktor ;

Johnson, Peter ;

Spurgeon, Stephen E. ;

Li, Lei ;

Zhang, Liang ;

Newberry, Kate ;

Ou, Zhishuo ;

Cheng, Nancy ;

Fang, Bingliang ;

McGreivy, Jesse ;

Clow, Fong ;

Buggy, Joseph J. ;

Chang, Betty Y. ;

Beaupre, Darrin M. ;

Kunkel, Lori A. ;

Blum, Kristie A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06) :507-516

← 1 2 3 →